Based on the above evidence, and although results were modest, clinical trials evaluating the efficacy of insulin sensitizers such as metformin and rosiglitazone suggested improvement in insulin sensitivity and cognitive impairment in AD patients (Kellar and Craft, 2020). This evidence concerns the gene INS and Alzheimer disease.